Literature DB >> 8230445

Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis.

W Paxton1, R I Connor, N R Landau.   

Abstract

The product of the vpr open reading frame of human immunodeficiency virus type 1 (HIV-1) is a 15-kDa, arginine-rich protein that is present in virions in molar quantities equivalent to that of Gag. We report here the results of our investigations into the mechanism by which Vpr is incorporated into virions during assembly in infected cells. For these studies we used an expression vector encoding a Vpr molecule fused at its amino terminus to a nine-amino-acid peptide from influenza virus hemagglutinin. The tagged Vpr expression vector and a vpr mutant HIV-1 provirus were used to cotransfect COS cells, and the resulting virions were tested for the presence of the tagged protein on immunoblots probed with monoclonal antibody against the hemagglutinin peptide. The COS-produced virions were found to contain readily detectable amounts of tagged Vpr and smaller amounts of a putative tagged Vpr dimer. Infectivity of the particles was not altered by incorporation of tagged Vpr. Our results using this system in combination with mutant HIV-1 proviruses suggested that incorporation of Vpr into virions requires the carboxy-terminal Gag protein of HIV-1 (p6) but not gp160, Pol, or genomic viral RNA. In addition, analysis of mutated, tagged Vpr molecules suggested that amino acids near the carboxy terminus (amino acids 84 to 94) are required for incorporation of Vpr into HIV-1 virions. The single cysteine residue near the carboxy terminus was required for production of a stable protein. Arginine residues tested were not important for incorporation or stability of tagged Vpr. These results suggested a novel strategy for blocking HIV-1 replication.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8230445      PMCID: PMC238185     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  The human immunodeficiency virus type 2 vpr gene is essential for productive infection of human macrophages.

Authors:  N Hattori; F Michaels; K Fargnoli; L Marcon; R C Gallo; G Franchini
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  A mutant of human immunodeficiency virus with reduced RNA packaging and abnormal particle morphology.

Authors:  F Clavel; J M Orenstein
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 Pr55gag and Pr160gag-pol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into viruslike particles.

Authors:  A J Smith; M I Cho; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

4.  Human immunodeficiency virus vpr product is a virion-associated regulatory protein.

Authors:  E A Cohen; G Dehni; J G Sodroski; W A Haseltine
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

5.  Open reading frame vpr of simian immunodeficiency virus encodes a virion-associated protein.

Authors:  X F Yu; M Matsuda; M Essex; T H Lee
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

6.  Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range.

Authors:  N R Landau; K A Page; D R Littman
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

7.  Induction of cell differentiation by human immunodeficiency virus 1 vpr.

Authors:  D N Levy; L S Fernandes; W V Williams; D B Weiner
Journal:  Cell       Date:  1993-02-26       Impact factor: 41.582

8.  Intracellular transport and virion incorporation of vpx requires interaction with other virus type-specific components.

Authors:  J C Kappes; J S Parkin; J A Conway; J Kim; C G Brouillette; G M Shaw; B H Hahn
Journal:  Virology       Date:  1993-03       Impact factor: 3.616

9.  Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines.

Authors:  L O Arthur; J W Bess; R C Sowder; R E Benveniste; D L Mann; J C Chermann; L E Henderson
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

10.  Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus.

Authors:  S M Lang; M Weeger; C Stahl-Hennig; C Coulibaly; G Hunsmann; J Müller; H Müller-Hermelink; D Fuchs; H Wachter; M M Daniel
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

View more
  166 in total

1.  Efficient DNA transfection mediated by the C-terminal domain of human immunodeficiency virus type 1 viral protein R.

Authors:  A Kichler; J C Pages; C Leborgne; S Druillennec; C Lenoir; D Coulaud; E Delain; E Le Cam; B P Roques; O Danos
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr.

Authors:  S P Singh; B Tomkowicz; D Lai; M Cartas; S Mahalingam; V S Kalyanaraman; R Murali; A Srinivasan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 Vpr-mediated G(2) cell cycle arrest: Vpr interferes with cell cycle signaling cascades by interacting with the B subunit of serine/threonine protein phosphatase 2A.

Authors:  M Hrimech; X J Yao; P E Branton; E A Cohen
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

4.  Nuclear export of human immunodeficiency virus type 1 Vpr is not required for virion packaging.

Authors:  Y Jenkins; P V Sanchez; B E Meyer; M H Malim
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag).

Authors:  Y Jenkins; O Pornillos; R L Rich; D G Myszka; W I Sundquist; M H Malim
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 6.  Viral late domains.

Authors:  Eric O Freed
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest.

Authors:  M P Sherman; C M de Noronha; D Pearce; W C Greene
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

8.  Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative.

Authors:  Barbara Müller; Jessica Daecke; Oliver T Fackler; Matthias T Dittmar; Hanswalter Zentgraf; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

9.  p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.

Authors:  M Huang; J M Orenstein; M A Martin; E O Freed
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles.

Authors:  Y L Lu; R P Bennett; J W Wills; R Gorelick; L Ratner
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.